Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Cortes, J. E., Kantarjian, H., Foran, J. M., Ghirdaladze, D., Zodelava, M., Borthakur, G., Gammon, G., Trone, D., Armstrong, R. C., James, J., Levis, M.Volume:
31
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2013.48.8783
Date:
October, 2013
File:
PDF, 458 KB
english, 2013